STOCK TITAN

QIAGEN N.V. - QGEN STOCK NEWS

Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.

QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.

QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.

QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Recent achievements include:

  • Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
  • Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
  • The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
  • Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
  • Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
  • Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
  • New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.

QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq: SOPH) has entered into a partnership with QIAGEN (NYSE: QGEN) to integrate QIAseq reagent technology with its SOPHiA DDM™ platform. This collaboration aims to enhance tumor analysis through next-generation sequencing (NGS), specifically supporting somatic variant detection related to homologous recombination repair. The partnership allows customers to access QIAseq panels for improved data analysis, enhancing research capabilities in oncology. Both companies are optimistic about the positive impact on medicine and research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
partnership
-
Rhea-AI Summary

QIAGEN has announced the certification of its QuantiFERON-TB Gold Plus test under the new EU In Vitro Diagnostic Medical Devices Regulation (IVDR), classified as Class C. This certification marks a key milestone in QIAGEN's compliance with EU regulations aimed at enhancing diagnostic performance and safety. The QuantiFERON-TB Gold Plus test is recognized globally, including by WHO, for its effectiveness in detecting tuberculosis. As part of its commitment, QIAGEN is transitioning over 180 products to meet the IVDR standards, ensuring continued supply and compliance moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
-
Rhea-AI Summary

QIAGEN N.V. (NYSE: QGEN) reported Q4 2022 net sales of $498 million, a 14% decline year-over-year, with sales at constant exchange rates (CER) at $531 million. The adjusted diluted EPS was $0.53, exceeding expectations. Non-COVID product sales grew 15% to $432 million. For full-year 2022, net sales were $2.14 billion with a 5% decline but profits were strong, showing adjusted diluted EPS of $2.38. Looking ahead, QIAGEN aims for 2023 net sales of at least $2.05 billion with continued growth in non-COVID products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
covid-19
Rhea-AI Summary

QIAGEN has launched the EZ2 Connect MDx platform for diagnostic laboratories, enhancing sample processing capabilities 18 months after its research introduction. This automated device purifies DNA and RNA from 24 samples in approximately 30 minutes and is CE-IVD compliant, enabling its use across the EU, U.S., Canada, and more. With over 5,000 EZ platforms deployed globally, EZ2 Connect MDx integrates with the QIAsphere digital system for remote management, meeting the fast-paced demands of clinical diagnostics. It addresses various sample types, employing magnetic-bead technology and ensuring high process safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
Rhea-AI Summary

QIAGEN N.V. (NYSE: QGEN) has announced its upcoming fourth quarter and full-year 2022 results, set to be released on February 7 at 22:05 Frankfurt time. Following this, a conference call is scheduled for February 8 at 15:00 Frankfurt time, where key business updates and financial performance will be discussed. The company provides solutions in molecular diagnostics, applied testing, pharma, and academia, serving over 500,000 customers globally. As of September 30, 2022, QIAGEN employed over 6,200 people across 35 locations worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
Rhea-AI Summary

QIAGEN has announced the completion of its acquisition of Verogen for $150 million in cash, enhancing its position in the next-generation sequencing (NGS) market for forensic applications. This acquisition follows a partnership that began in June 2021 and is expected to generate $20 million in sales from Verogen’s offerings in 2023. However, it will be dilutive to QIAGEN’s adjusted EPS by about $0.03 per share for 2023. The integration of Verogen’s technology is anticipated to broaden QIAGEN’s capabilities in human identification and forensic investigations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
Rhea-AI Summary

QIAGEN has entered an exclusive partnership with Helix to enhance companion diagnostics for hereditary diseases. The collaboration will utilize Helix's laboratory platform and QIAGEN's regulatory expertise to accelerate patient recruitment and real-world evidence generation. This partnership aims to provide innovative diagnostic solutions for neuro-degenerative, cardiovascular, and autoimmune diseases, benefiting hundreds of millions globally. QIAGEN will exclusively market Helix's companion diagnostic services in the U.S., leveraging their extensive network and experience in precision medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
partnership
-
Rhea-AI Summary

Helix and QIAGEN have announced a global strategic partnership to co-develop companion diagnostics for hereditary diseases. This collaboration will utilize the Helix Laboratory Platform alongside QIAGEN's diagnostic technologies. The partnership aims to tackle significant health issues, such as neuro-degenerative and cardiovascular diseases. Helix's platform is the first FDA-approved Class II diagnostic system, enhancing patient recruitment for clinical trials. The two companies plan to reveal further details at the upcoming JPMorgan Health Care Conference in San Francisco.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
partnership
-
Rhea-AI Summary

QIAGEN has received FDA approval for its therascreen KRAS RGQ PCR kit as a companion diagnostic for KRAZATI (adagrasib), targeting non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. This marks the 4th approval of the kit, expanding treatment options for an underserved population with high unmet needs. The kit is designed for fast, cost-effective testing, allowing for timely and informed treatment decisions. QIAGEN's advancements reflect strong collaboration with Mirati Therapeutics and underscore their leadership in RAS companion diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
Rhea-AI Summary

QIAGEN N.V. (NYSE: QGEN) reported Q3 2022 net sales of $500 million, down 7% year-over-year, but above expectations of $510 million at constant exchange rates (CER). Adjusted diluted EPS was $0.53, exceeding a forecast of $0.48 CER. Notably, the non-COVID product portfolio saw 18% CER growth to $417 million. The company raised its full-year sales outlook to $2.25 billion CER and adjusted diluted EPS to $2.40 CER, reflecting strong cash flow and robust demand for its solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.6%
Tags
covid-19

FAQ

What is the current stock price of QIAGEN N.V. (QGEN)?

The current stock price of QIAGEN N.V. (QGEN) is $44.68 as of January 10, 2025.

What is the market cap of QIAGEN N.V. (QGEN)?

The market cap of QIAGEN N.V. (QGEN) is approximately 9.9B.

What does QIAGEN N.V. do?

QIAGEN N.V. provides sample-to-insight solutions that transform biological materials into valuable molecular insights, serving sectors such as healthcare, forensics, pharma, and academia.

How many employees does QIAGEN N.V. have?

As of June 30, 2015, QIAGEN employed approximately 4,400 people across over 35 locations worldwide.

What are QIAGEN's recent financial achievements?

In Q1 2024, QIAGEN reported net sales of $459 million and a strong operating cash flow, rising 85% to $133 million compared to Q1 2023.

What industries does QIAGEN serve?

QIAGEN serves the molecular diagnostics, applied testing, pharma, and academia sectors.

What are QIAGEN’s proprietary technologies?

QIAGEN's proprietary technologies include sample and assay technologies for isolating, processing, and interpreting DNA, RNA, and proteins.

Where can I find more information about QIAGEN?

More information about QIAGEN can be found on their official website at http://www.qiagen.com.

What are some of QIAGEN's recent innovations?

Recent innovations include the QCI Secondary Analysis software, novel digital PCR assays for forensics, and enhancements to the QIAGEN Clinical Insight Interpret platform.

How is QIAGEN's revenue split?

QIAGEN's revenue is almost evenly split between life sciences and molecular diagnostics, with nearly 90% from consumables and the rest from instrumentation and services.

Which regions contribute most to QIAGEN's revenue?

The Americas contribute over 45% of QIAGEN's sales, followed by EMEA (nearly 35%) and Asia-Pacific (nearly 20%).

What is the QIAstat-Dx Respiratory Panel Plus?

The QIAstat-Dx Respiratory Panel Plus is a diagnostic tool designed for accurate and rapid detection of respiratory infections, producing results in about one hour.
QIAGEN N.V.

Nasdaq:QGEN

QGEN Rankings

QGEN Stock Data

9.93B
217.27M
2.24%
87.87%
1.68%
Diagnostics & Research
Healthcare
Link
United States of America
Venlo